Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

PACIRA BIOSCIENCES, INC.

(PCRX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Pacira BioSciences to Participate in Fireside Chat at the 2022 Wedbush PacGrow Healthcare Virtual Conference

08/02/2022 | 08:01am EDT

TAMPA, Fla., Aug. 02, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the 2022 Wedbush PacGrow Healthcare Virtual Conference at 11:30 AM ET on Wednesday, August 10, 2022. Live audio of the event can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event.

About Pacira         

Pacira BioSciences, Inc. (Nasdaq: PCRX) is committed to providing a non-opioid option to as many patients as possible to redefine the role of opioids as rescue therapy only. The company is also developing innovative interventions to address debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain, and spasticity. Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting, local analgesia currently approved for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular, injection indicated for the management of osteoarthritis knee pain; and ioveraº®, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit www.pacira.com.



Company Contact:
Pacira BioSciences, Inc.
Christian Pedetti
(973) 254-4387
Christian.pedetti@pacira.com

Primary Logo

Source: Pacira BioSciences

2022 GlobeNewswire, Inc., source Press Releases

All news about PACIRA BIOSCIENCES, INC.
09/27Pacira BioSciences, Sevaredent Partner Over Expanded Access to Exparel for Patients Und..
MT
09/27Sevāredent Sourcing Solutions and Pacira BioSciences Collaborate to Provide Expand..
GL
09/27Sevāredent Sourcing Solutions and Pacira BioSciences Collaborate to Provide Expand..
AQ
09/27Sevaredent Sourcing Solutions and Pacira BioSciences, Inc. Collaborate to Provide Expan..
CI
09/21Pacira BioSciences Announces Positive Topline Data from Phase 3 Study of EXPAREL as a S..
GL
09/21Pacira BioSciences Announces Positive Topline Data from Phase 3 Study of EXPAREL as a S..
GL
09/21Pacira Biosciences Announces Positive Topline Data from Phase 3 Study of Exparel as A S..
CI
09/20Pacira BioSciences Receives Positive Opinion for Post-Surgical Pain Treatment in Childr..
MT
09/20Pacira Receives Positive CHMP Opinion for EXPAREL® for the Treatment of Postsurgical Pa..
GL
09/20Pacira BioSciences, Inc. Receives Positive CHMP Opinion for Exparel® for the Treatment ..
CI
More news
Analyst Recommendations on PACIRA BIOSCIENCES, INC.
More recommendations
Financials (USD)
Sales 2022 691 M - -
Net income 2022 86,9 M - -
Net Debt 2022 510 M - -
P/E ratio 2022 32,3x
Yield 2022 -
Capitalization 2 486 M 2 486 M -
EV / Sales 2022 4,33x
EV / Sales 2023 3,39x
Nbr of Employees 697
Free-Float 98,8%
Chart PACIRA BIOSCIENCES, INC.
Duration : Period :
Pacira BioSciences, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PACIRA BIOSCIENCES, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Last Close Price 54,24 $
Average target price 78,20 $
Spread / Average Target 44,2%
EPS Revisions
Managers and Directors
David M. Stack Chairman & Chief Executive Officer
Charles A. Reinhart Chief Financial Officer
Roy Winston Chief Medical Officer
Charles Anthony Laranjeira Senior Vice President-Technical Operations
Jonathan Slonin Chief Clinical Officer
Sector and Competitors
1st jan.Capi. (M$)
PACIRA BIOSCIENCES, INC.-9.86%2 481
JOHNSON & JOHNSON-3.82%437 390
ELI LILLY AND COMPANY21.06%317 719
ROCHE HOLDING AG-14.15%273 173
ABBVIE INC.6.79%255 667
PFIZER, INC.-25.22%249 357